Short answer
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) filed its Q1 2026 10-Q quarterly report on Mar 17, 2026 for the quarter ended Jan 31, 2026. Quarterly revenue was $36M with net income of −$49M.
Q1 2026 key financials · XBRL
- Revenue
- $36M
- +57.4% QoQ
- Net income
- −$49M
- −48.5% QoQ
- Operating margin
- -162.6%
- Gross margin
- 44.2%
- EPS (diluted)
- −$1.01
- −57.8% QoQ
Source: XBRL data from the KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) Q1 2026 10-Q on SEC EDGAR. USD.
KESTRA MEDICAL TECHNOLOGIES, LTD. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Risk Factors section absent from provided text, preventing identification of newly added or materially changed risks
- Regulatory risk: maintaining ASSURE WCD approvals and securing clearances for new markets or products
- Operational risk: scaling manufacturing while securing timely component supplies and managing inventory
- Market risk: uncertain acceptance of ASSURE WCD and availability of product reimbursement
- Financial risk: increased expenses associated with public-company status
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other KESTRA MEDICAL TECHNOLOGIES, LTD. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.